Technical Data Sheet

Purified Mouse Anti-p53


Product Information

| Material Number: 5541 | 66 |
|-----------------------|---|
| Size: 0.1 r | ng |
| Concentration: 0.5 r | ng/ml |
| Clone: PAb | 240 |
| Immunogen: Hum | an p53 aa. 14-289 |
| Isotype: Mou | se IgG1 |
| Reactivity: QC | Festing: Human, Mouse, Rat, Hamster, Monkey, Bovine, Chicken |
| Target MW: 53 k | Da |
| Storage Buffer: Aqu | eous buffered solution containing $\leq 0.09\%$ sodium azide. |

Description

p53 is a nuclear phosphoprotein which acts as a tumor suppressor by providing a cell cycle checkpoint for DNA damage during S-phase. Mutations in wildtype p53 can indirectly alter the DNA binding and transcription factor activity of p53. By altering expression of genes normally regulated by p53, these mutations can result in both a loss of tumor suppressor function and a gain of oncogenic function. The majority of mutations in the p53 gene are missense mutations which alter the identity of an amino acid. These mutations may alter the conformation and thus increase the stability of the mutant p53 protein. p53 is expressed in all vertebrate species examined. p53 may be overexpressed in transformed cell lines, where it forms complexes with viral oncogenes including SV40 large T antigen and the adenovirus protein, E1B. p53 migrates at ~53 kDa on SDS-PAGE.

PAb 240 reacts with a conformational epitope between amino acids 156 and 214 of native p53. As such, Pab 240 recognizes only certain mutant forms of p53, as determined by immunoprecipitation. It detects both mutant and wildtype p53 in western blot analysis and immunohistochemistry of frozen tissue sections. It is thought that p53 mutations exert a common conformational change which results in expression of the Pab 240-specific epitope on mutant p53 molecules. A recombinant fusion protein of p53 sequence including amino acids 14-289 was used as immunogen.



Preparation and Storage

The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. Store undiluted at 4°C.

Application Notes

| A | pplication | | | |
|---|-------------------------------|---------------------------|--|--|
| | Western blot | Routinely Tested | | |
| | Immunohistochemistry-frozen | Tested During Development | | |
| | Immunoprecipitation | Tested During Development | | |
| | Immunohistochemistry-paraffin | Not Recommended | | |

BD Biosciences

| bdbiosciences. | om | | | | |
|--|---|---|--|---|--|
| United States 877.232.8995 | Canada 888.259.0187 | Europe 32,53,720,550 | Japan 0120.8555.90 | Asia Pacific 65.6861.0633 | Latin America/Caribbean 55.11.5185.9995 |
| | | | | | |
| | | | bdbiosciences.co | | |
| of any patents. BL use of our produc product or as a co written authoriza For Research Use | Biosciences will no ts. Purchase does n mponent of anoth tion of Becton Dick Dnly. Not for use in | ot be held responsi ot include or carry er product. Any us inson and Compan diagnostic or there | ble for patent infring any right to resell or | gement or other vio transfer this produ- er than the permitt d. Not for resale. | the above product in violation lations that may occur with the ct either as a stand-alone ed use without the express 8D |

Recommended Assay Procedure:

SV40-transformed COS-7 monkey kidney cells (ATCC CRL-1651) or other SV40-transformed cell lines are suggested as positive controls. Please refer to http://www.bdbiosciences.com/pharmingen/protocols/Western_Blotting.shtml, for Western blot protocols.

Product Notices

- 1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
- 2. Please refer to www.bdbiosciences.com/pharmingen/protocols for technical protocols.
- Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.

References

Bartek J, Bartkova J, Vojtesek B, et al. Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. *Oncogene*. 1991; 6(9):1699-1703.(Clone-specific: Immunohistochemistry)

Gannon JV, Greaves R, Iggo R, Lane DP. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. *EMBO J.* 1990; 9(5):1595-1602.(Clone-specific: Immunoprecipitation, Western blot)

Jacquemier J, Moles JP, Penault-Llorca F, et al. p53 immunohistochemical analysis in breast cancer with four monoclonal antibodies: comparison of staining and PCR-SSCP results. *Br J Cancer*. 1994; 69(5):846-852. (Clone-specific: Immunohistochemistry)

Moore M, Teresky AK, Levine AJ, Seiberg M. p53 mutations are not selected for in simian virus 40 T-antigen-induced tumors from transgenic mice. J Virol. 1992; 66(2):641-649.(Clone-specific: Immunoprecipitation)

Said JW, Barrera R, Shintaku IP, Nakamura H, Koeffler HP. Immunohistochemical analysis of p53 expression in malignant lymphomas. *Am J Pathol.* 1992; 141(6):1343-1348.(Clone-specific: Immunohistochemistry, Immunoprecipitation)

Vojtesek B, Bartek J, Midgley CA, Lane DP. An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Methods. 1992; 151(1-2):237-244. (Clone-specific: Immunohistochemistry)

Walker RA, Dearing SJ, Lane DP, Varley JM. Expression of p53 protein in infiltrating and in-situ breast carcinomas. J Pathol. 1991; 165(3):203-211. (Clone-specific: Immunohistochemistry)